Last updated: September 21, 2026
Omadacycline tosylate, marketed as Nuzyra by Paratek Pharmaceuticals, is a branded aminomethylcycline antibiotic approved for adults with acute bacterial skin and skin-structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Its commercial trajectory has been driven by rising net product sales, expansion across hospital and outpatient settings, and demand for an oral and intravenous antibiotic that avoids several established tetracycline-resistance mechanisms.
Paratek reported net product sales of about $186 million in 2023, up from approximately $150 million in 2022. The company was acquired by Gurnet Point Capital and Novo Holdings in 2023 for approximately $462 million, transferring Nuzyra into private ownership and ending routine public-market disclosure of product-level revenue.[1,2]
What is omadacycline tosylate and how is Nuzyra used?
Omadacycline is a tetracycline-class antibiotic with oral and intravenous formulations. The FDA approved Nuzyra in October 2018 for adult patients with ABSSSI and in March 2019 for adult patients with CABP.[3,4]
What differentiates omadacycline from older tetracyclines?
Omadacycline was designed to retain activity against organisms carrying common tetracycline-resistance mechanisms, including ribosomal protection and efflux mechanisms. Its clinical positioning includes:
- Oral and intravenous dosing options.
- Once-daily administration after loading.
- Activity against key gram-positive and atypical respiratory pathogens.
- No requirement for therapeutic drug monitoring.
- Use in patients for whom fluoroquinolones, macrolides, beta-lactams or older tetracyclines are unsuitable.
The drug is not positioned as a broad replacement for all hospital antibiotics. Its commercial value depends on targeted use in complicated infections, antibiotic stewardship protocols, outpatient infusion programs and patients with limited treatment options.
The FDA label includes a boxed warning for increased all-cause mortality observed in the CABP trial compared with moxifloxacin or linezolid. The label states that Nuzyra should be reserved for CABP when alternative antibacterial treatments are not suitable.[3] That warning limits unrestricted use in pneumonia and affects formulary positioning.
How large is the omadacycline market opportunity?
Omadacycline competes in a large infection market, but only a narrow segment is accessible to a premium branded antibiotic.
What are the main commercial demand drivers?
The principal demand drivers are:
- Rising antimicrobial resistance.
- Need for oral step-down therapy after intravenous treatment.
- Avoidance of drug-drug interactions associated with some alternatives.
- Expansion of hospital-at-home and outpatient parenteral antibiotic programs.
- Treatment of patients with allergies or resistance to beta-lactams, macrolides or fluoroquinolones.
- Institutional efforts to reduce avoidable hospital admissions.
ABSSSI is the stronger commercial anchor because it permits use without the CABP mortality warning. CABP remains clinically relevant, but the boxed warning makes hospitals more selective.
Nuzyra also benefits from availability in both oral tablets and intravenous formulations. This supports an early intravenous dose followed by oral treatment, potentially reducing inpatient days and infusion costs. The financial benefit to hospitals depends on whether the product is used to avoid admission, accelerate discharge or replace less convenient outpatient regimens.
How does omadacycline compare with competing antibiotics?
| Drug |
Company or market status |
Main indications |
Oral option |
Commercial impact on Nuzyra |
| Omadacycline |
Paratek |
ABSSSI, CABP |
Yes |
Branded direct competitor to newer agents |
| Eravacycline |
Tetraphase, acquired by Melinta |
Complicated intra-abdominal infection |
No |
Competes mainly in hospital IV treatment |
| Lefamulin |
Nabriva, acquired by Innoviva |
CABP |
Yes |
Direct CABP competitor with oral and IV use |
| Delafloxacin |
Melinta |
ABSSSI, CABP |
Yes |
Competes across both approved Nuzyra indications |
| Linezolid |
Generic and branded |
Serious gram-positive infections, including pneumonia |
Yes |
Low-cost oral alternative |
| Doxycycline |
Generic |
Broad infectious disease use |
Yes |
Major price and prescribing constraint |
| Tedizolid |
Merck and generic markets |
ABSSSI |
Yes |
Competes in gram-positive skin infections |
| Fluoroquinolones |
Multiple generic manufacturers |
Respiratory and other infections |
Yes |
Low-cost alternatives, limited by safety concerns |
| Vancomycin |
Generic |
Serious gram-positive infections |
Limited oral utility for systemic infection |
Remains a hospital standard for MRSA |
Nuzyra's commercial differentiation is strongest against generic alternatives when the prescriber values resistance coverage, oral-to-IV flexibility or avoidance of toxicity associated with competing agents. Its differentiation is weaker when price is the dominant factor.
What was the financial trajectory of Nuzyra?
Paratek's reported product sales grew steadily before the company went private.
| Fiscal year |
Approximate Nuzyra net product sales |
Year-over-year change |
| 2020 |
$94 million |
Not comparable due to launch and pandemic effects |
| 2021 |
$140 million |
Approximately 48% |
| 2022 |
$150 million |
Approximately 7% |
| 2023 |
$186 million |
Approximately 24% |
Sources: Paratek annual reports and public company disclosures.[1,5,6]
Why did sales continue growing after launch?
Nuzyra launched in a difficult hospital market. The COVID-19 pandemic disrupted elective procedures, infectious-disease consultation and hospital access. Paratek then expanded its commercial model across hospital accounts, infectious-disease specialists, emergency departments and outpatient settings.
The 2023 sales increase reflected higher demand, broader account penetration and improved utilization in ABSSSI. The company also reported growth in prescriptions and hospital adoption in its public disclosures.[1]
Revenue quality was commercially attractive because the product had two dosage forms and a relatively high branded price compared with generic tetracyclines. The principal constraint was payer and formulary control. Hospitals frequently require prior authorization, antimicrobial stewardship approval or infectious-disease consultation before using newer antibiotics.
What was the acquisition value of Paratek and Nuzyra?
Gurnet Point Capital and Novo Holdings agreed to acquire Paratek in 2023 in a transaction valued at approximately $462 million, including assumed debt and other transaction considerations. The per-share consideration was approximately $2.15.[2]
The acquisition valuation implied a modest multiple of reported annual sales. Using 2023 net product sales of approximately $186 million, the transaction value equaled roughly 2.5 times annual product revenue. That multiple reflected the difference between commercial revenue and economic profit. Nuzyra required continuing sales, medical-affairs, market-access and postmarketing investment, while its addressable market remained limited by generic competition and antibiotic stewardship.
The transaction also gave the buyers control of a marketed antibiotic with established FDA approvals, commercial infrastructure and additional geographic rights. The private ownership structure allows the sponsors to manage pricing, market expansion and lifecycle investment without quarterly public-market reporting.
When does omadacycline lose exclusivity?
Nuzyra's commercial exclusivity depends on several overlapping protections rather than a single date.
What regulatory exclusivity did Nuzyra receive?
The FDA granted Nuzyra five years of new chemical entity exclusivity following the 2018 approval. The CABP approval in 2019 expanded the label but did not create a second five-year NCE period.[3,4]
Nuzyra also received qualified infectious disease product status under the Generating Antibiotic Incentives Now framework. That designation provided an additional five years of exclusivity under the applicable statutory framework. The commercial effect was to defer certain generic competition beyond the normal Hatch-Waxman exclusivity period.[7]
What patents protect omadacycline?
The U.S. patent estate includes composition-of-matter, pharmaceutical-composition and method-of-use protections associated with omadacycline and its formulations. Public FDA and patent records identify issued patents covering the active ingredient and related uses, with relevant protection extending beyond the initial five-year regulatory exclusivity period.[8,9]
The most important commercial protections are:
- Composition and chemical-structure claims.
- Salt and pharmaceutical-composition claims.
- Oral tablet and intravenous formulation claims.
- Treatment claims for bacterial infections.
- Claims directed to dosing and administration.
The strength of the estate depends on claim scope, patent-term adjustment, terminal disclaimers, validity challenges and the ability of a generic applicant to design around formulation or method claims. Composition claims generally provide the strongest barrier. Method-of-use and formulation claims can still delay entry, but they are more vulnerable to labeling strategies and invalidity arguments.
What is the Orange Book status of Nuzyra?
Nuzyra's approved product and relevant patent information are listed in the FDA Orange Book. Orange Book listings can support patent litigation after a Paragraph IV certification and can create a 30-month stay of approval under the Hatch-Waxman Act, subject to statutory requirements and litigation outcomes.[8]
The precise generic-entry date depends on the listed patent set, pediatric exclusivity, any patent-term adjustment, settlement terms and the timing of an abbreviated new drug application. A single patent expiration date should not be treated as the entire exclusivity profile.
Are generic manufacturers challenging omadacycline?
Publicly disclosed information has not established a broad, commercially active generic challenge comparable to the challenge history of major small-molecule blockbusters. No biosimilar pathway applies because omadacycline is a chemically synthesized small molecule, not a biologic.
What would a Paragraph IV challenge mean?
A generic applicant could file an ANDA with a Paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable or not infringed. If the patent holder sued within 45 days, FDA approval could be stayed for up to 30 months unless the court resolves the case earlier or the stay is otherwise terminated.[8]
A generic launch could occur through several scenarios:
| Scenario |
Commercial effect |
| No challenge before key patent expiry |
Nuzyra retains branded pricing until patent and regulatory barriers expire |
| Paragraph IV settlement with delayed entry |
Generic entry occurs on an agreed date, often before the latest patent expiry |
| Successful patent challenge |
Earlier generic entry and rapid price erosion |
| At-risk generic launch |
Potential immediate price pressure followed by damages exposure |
| Authorized generic |
Brand owner or licensee supplies a generic version, limiting third-party economics |
The most material risk is not biosimilar substitution. It is an ANDA-based generic challenge to the active ingredient, salt, formulation or use patents.
What is the FDA regulatory status of omadacycline?
Nuzyra is FDA-approved for adults with ABSSSI caused by susceptible gram-positive and gram-negative bacteria and for CABP caused by susceptible organisms, subject to the limitations and warnings in the prescribing information.[3]
The product is not approved for pediatric use. The FDA label also warns against administration with food, dairy products and certain multivalent cations because absorption can be reduced. These administration restrictions can affect adherence and prescribing preference relative to simpler oral antibiotics.
The CABP mortality warning remains a central regulatory and commercial factor. It narrows the drug's use in pneumonia and makes label-compliant positioning important in hospital protocols.
What licensing deals and geographic rights affect Nuzyra?
Paratek developed and commercialized Nuzyra in the United States. The company also entered into arrangements covering commercialization and development rights outside the U.S., including regional partnerships and licensing structures disclosed in its corporate filings.[1,5]
The value of international rights is lower than U.S. rights because antibiotic pricing, reimbursement and regulatory access vary sharply by country. The United States remains the principal value driver because it has the highest branded pricing and the most developed hospital market-access infrastructure.
How strong is the omadacycline patent estate?
The estate is commercially meaningful but not immune to challenge.
Strengths
- A marketed small-molecule product with composition-related protection.
- Two FDA-approved indications.
- Oral and intravenous dosage forms.
- Qualified infectious disease product exclusivity.
- Hospital and outpatient use cases.
- Limited direct generic availability at present.
Weaknesses
- Strong competition from low-cost doxycycline, linezolid and other generics.
- Antibiotic stewardship restrictions.
- CABP boxed warning.
- Formulary substitution pressure.
- Potential ANDA design-around strategies for formulation and method claims.
- Limited ability to expand use beyond approved infections without new clinical evidence.
The estate is strongest as a medium-term protection platform for continued branded sales. It is less likely to support rapid expansion into broad first-line antibiotic use.
What revenue exposure exists if a generic launches?
Generic entry would likely produce a steep decline in average selling price, followed by volume substitution. The magnitude would depend on whether the generic covers both oral tablets and intravenous formulations, whether multiple manufacturers enter simultaneously and whether the brand retains hospital contracts.
A reasonable commercial framework is:
- Before generic entry: price and formulary expansion remain the main growth levers.
- First generic entry: net price pressure begins, with hospital accounts seeking discounts.
- Multiple generic entry: rapid price erosion and reduced branded share.
- Post-exclusivity market: Nuzyra could retain a niche in patients requiring its resistance profile or oral-IV flexibility, but revenue would likely be materially below the branded peak.
Because 2023 sales were approximately $186 million, even a moderate erosion rate would materially reduce asset value. The acquisition thesis therefore depends on extending the period of branded growth, improving payer access and preserving use in high-value patients before generic competition becomes active.
Key Takeaways
- Nuzyra is the branded formulation of omadacycline, approved for ABSSSI and CABP.
- U.S. net product sales reached approximately $186 million in 2023, compared with $150 million in 2022.
- Paratek was acquired by Gurnet Point Capital and Novo Holdings in 2023 for approximately $462 million.
- ABSSSI is the stronger commercial indication; CABP use is constrained by the FDA boxed warning on increased all-cause mortality.
- The product competes against generic doxycycline, linezolid, fluoroquinolones, vancomycin and newer branded antibiotics.
- Regulatory exclusivity included five-year NCE exclusivity and additional qualified infectious disease product protection.
- Generic risk is based on Hatch-Waxman ANDA litigation, not biosimilar substitution.
- The patent estate has composition, formulation and method-of-use dimensions, but exact generic-entry timing depends on the current Orange Book listing and any Paragraph IV settlements.
- The principal financial risk is rapid price erosion after generic entry, while the principal near-term opportunity is continued hospital and outpatient penetration.
FAQs
Is omadacycline the same as doxycycline?
No. Omadacycline is a newer aminomethylcycline designed to retain activity against certain tetracycline-resistance mechanisms. Doxycycline is an older generic tetracycline with a substantially lower price.
Does Nuzyra have an oral formulation?
Yes. Nuzyra is available as oral tablets and as an intravenous formulation. The two-formulation profile supports hospital initiation followed by oral treatment.
Is Nuzyra approved for urinary tract infections?
No. FDA approvals cover ABSSSI and CABP in adults. Use for other infections would generally be outside the approved label.
Can a generic manufacturer substitute for Nuzyra automatically?
Automatic substitution depends on FDA therapeutic-equivalence status, state pharmacy law and the specific dosage form. Hospital use is also controlled by formularies, contracts and antimicrobial stewardship policies.
Does omadacycline have biosimilar competition?
No. Omadacycline is a small-molecule chemical drug. Any future competition would generally proceed through the ANDA generic pathway rather than the biosimilar pathway.
References
-
Paratek Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Paratek Pharmaceuticals, Inc. (2023, October 31). Paratek Pharmaceuticals completes acquisition by Gurnet Point Capital and Novo Holdings. Company press release.
-
U.S. Food and Drug Administration. (2018). Nuzyra (omadacycline) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2019). FDA approves Nuzyra for community-acquired bacterial pneumonia. FDA.
-
Paratek Pharmaceuticals, Inc. (2022). Annual report on Form 10-K for the year ended December 31, 2021. U.S. Securities and Exchange Commission.
-
Paratek Pharmaceuticals, Inc. (2023). Annual report on Form 10-K for the year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
U.S. Congress. (2012). Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, Title VIII. U.S. Government Publishing Office.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Patent and Trademark Office. (2024). Patent Center. USPTO.
